Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Cancers|November 13, 2025
High Rate of Cytokine Release Syndrome-Related Coagulopathy with Low Incidence of Bleeding and Thrombosis in Patients Treated with B-Cell Maturation Antigen (BCMA)-Targeted Chimeric Antigen Receptor T-Cells (CAR-T)Ariela Arad, Maya Katz, Eyal Lebel, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 7, 2020
Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life StudyEfrat Luttwak, Moshe E Gatt, Eyal Lebel, et al.
Haematologica|October 6, 2022
Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trialNathalie Asherie, Shlomit Kfir-Erenfeld, Batia Avni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2022
Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL AmyloidosisShlomit Kfir-Erenfeld, Nathalie Asherie, Sigal Grisariu, et al.
Leukemia & Lymphoma|May 2, 2022
Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphomaEyal Lebel, Neta Goldschmidt, Tali Siegal, et al.
Cancer|August 12, 2023
A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphomaOsnat Bairey, Alisa Taliansky, Amir Glik, et al.
Cancers|July 14, 2023
Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?Vladimir Vainstein, Batia Avni, Sigal Grisariu, et al.
Leukemia & Lymphoma|September 8, 2022
Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study GroupChezi Ganzel, Svetlana Trestman, Shai Levi, et al.
International Journal of Molecular Sciences|April 14, 2026
Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell TherapyIdo Cohen, Eyal Lebel, Sigal Grisariu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2024
Efficacy and Safety of Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL AmyloidosisEyal Lebel, Nathalie Asherie, Shlomit Kfir-Erenfeld, et al.
Pageof 4